# US 10,117,857 B2 · External medicine for diffuse plexiform neurofibroma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,857 B2
- Document ID: US10117857B2
- Status: Granted
- Kind: B2
- Application number: 15/559,322
- Filed: 2016-03-09
- Published: 2018-04-26
- Granted: 2018-11-06
- Earliest claimed: 2015-03-23
- Assignees: Osaka University
- Applicants: Osaka University
- Inventors: Mari Kaneda; Ichiro Katayama
- Web page: https://patentgrep.com/patent/US10117857B2

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An external medicine for diffuse plexiform neurofibromas is provided. The external medicine for diffuse plexiform neurofibromas in accordance with an embodiment of the present invention contains, as an active ingredient, at least one selected from the group consisting of sirolimus and sirolimus derivatives.

## Claims

### Claim 1

An external medicine for neurofibromas, comprising, (i) as an active ingredient, at least one selected from the group consisting of sirolimus, everolimus, temsirolimus, ridaforolimus, and zotarolimus and (ii) ethanol,
the ethanol being contained in an amount of 20 wt % to 60 wt %,
the active ingredient being contained in an amount of not less than 0.2 wt % and less than 0.8 wt %.

### Claim 2 (depends on 1)

The external medicine as set forth in claim 1 is a gel.

### Claim 3 (depends on 1)

The external medicine as set forth in claim 1, wherein the neurofibromas are diffuse plexiform neurofibromas.

### Claim 4

A method of performing a medical procedure or medical treatment for neurofibromas, comprising the step of administering an external medicine comprising, (i) as an active ingredient, at least one selected from the group consisting of sirolimus, everolimus, temsirolimus, ridaforolimus, and zotarolimus and (ii) ethanol,
the ethanol being contained in an amount of 20 wt % to 60 wt %,
the active ingredient being contained in an amount of not less than 0.2 wt % and less than 0.8 wt %.

### Claim 5 (depends on 4)

The method as set forth in claim 4, wherein the neurofibromas are diffuse plexiform neurofibromas.